Samuel Kayman

US Patent:

59524740, Sep 14, 1999

Filed:

Jul 1, 1997

Appl. No.:

8/886642

Inventors:

Samuel Kayman - New York NY
Abraham Pinter - Brooklyn NY

Assignee:

The Public Health Research Institute of the City of New York, Inc. - New York NY

International Classification:

C07K 1416
C07K 14435
C12P 2102
C12N 1585

US Classification:

530395

Abstract:

Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.

US Patent:

56437560, Jul 1, 1997

Filed:

Aug 20, 1993

Appl. No.:

8/110300

Inventors:

Samuel Kayman - New York NY
Abraham Pinter - Brooklyn NY

Assignee:

The Public Health Research Institute of the City of New York, Inc. - New York NY

International Classification:

C12N 510
C12N 1585
C12P 2102

US Classification:

435 697

Abstract:

Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.